Esperion Therapeutics | ESPR - Equity Capital And Reserves


Esperion Therapeutics reported $-451.36M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Alterity Therapeutics Limited AUD 22.81M 5.29M Jun/2023
Amarin USD 458.89M 6.03M Sep/2025
Amgen USD 8.66B 961M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Cipla INR 329.19B 16.3B Sep/2025
CSL USD 18.66B 2.75B Dec/2025
Cytokinetics USD -659.62M 138.5M Dec/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Geron USD 225.87M 22.83M Dec/2025
Grifols EUR 6.08B 34.72M Sep/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025